Early rectal cancer: opening the door to change
Mené sur 79 patients atteints d'un cancer de stade T2N0 de la partie distale du rectum et traités entre 2006 et 2009 (durée médiane de suivi : 56 mois), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans maladie à 3 ans, et les effets secondaires d'un traitement conservateur combinant une chimioradiothérapie néoadjuvante et une exérèse localisée
In The Lancet Oncology, Julio Garcia-Aguilar and colleagues1 report the results of an important, multi-institutional phase 2 trial for patients with clinically staged T2N0 rectal cancer. Patients received an intensive regimen of neoadjuvant radiotherapy combined with capecitabine and oxaliplatin followed by local excision. This combination seems highly active in small early cancers in terms of tumour response but might not be widely embraced because of the generally disappointing results of other phase 3 studies integrating oxaliplatin into chemoradiation in more locally advanced rectal cancer.
The Lancet Oncology , commentaire, 2014